"We need to work to find uses for any sort of biomarker," he explained. "There are possibilities that we could apply this information someday to a patient's prognosis, and for careful monitoring or increased surveillance if a person has a 2.5 times higher risk of dying, instead of letting them go their way after a CABG surgery."
Treatment outcomes also need to be tested according to a "personalized" susceptibility profile. The Duke Clinical Research Institute is known for its work with patients who have cardiac/coronary disease and testing when it is best to employ one of three therapeutic options: 1) medication only, 2) opening a clotted vessel with angioplasty and a stent, or 3) bypassing the clotted vessel with a graft from another vessel, as in CABG procedures, Podgoreanu said. "But at no point has genetic or biomarker information been superimposed on this care-improvement testing process, so the results of this preliminary study will provide ammo for more studies with a genetically stratified trial," he said.
The findings also may benefit patients someday, because genetic results are unchanging. "If we take saliva or blood from patients before surgery and find they carry this gene variant, we can be more sure about their risk profile, as opposed to simply measuring values of the protein product of that gene in their blood profiles that are subject to change, for example, in response to the stress of surgery or medications," Podgoreanu said.
|Contact: Mary Jane Gore|
Duke University Medical Center